Half Yearly Report and Accounts

Link to Full Article Adherium Limited ABN 24 605 352 510 Appendix 4D   Interim Consolidated Financial Report for the six months ended 31 December 2019   Adherium Limited (“Adherium”, the “Company” or the “Group”) presents this financial report, including the interim financial statements, for the six months ended 31 December   Results for announcement […]

ARECOR ACHIEVES SECOND LICENSE MILESTONE PAYMENT FROM GLOBAL PHARMACEUTICAL PARTNER

Link to Full Article Arecor formulated biosimilar product progressing through clinical studies Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered […]

Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.

Link to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]

ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY

Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]

Adherium Raises $5.4 million to Complete Rights Issue and Shortfall Placement

  Link to Full Article 11 February 2020 – Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has successfully reached its target of $5.4 million raised through its Rights Issue allocating 17,517,309 shares in entitlement subscriptions and 162,206,104 shortfall shares to wholesale and exempt […]